Momentum Builds: Bladder Cancer Trial Data Boost Seagen
- September 22nd, 2023
- 581 views
Astellas Pharma Inc. and Seagen Inc. (Nasdaq: SGEN) have reported promising results from the Phase 3 EV-302 clinical trial (KEYNOTE-A39) for PADCEV (enfortumab vedotin-ejfv) combined with Merck & Co., Inc.'s (NYSE: MRK) KEYTRUDA (pembrolizumab) versus traditional chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC), a severe form of bladder cancer that has spread.
The study achieved its primary endpoints, showing significantly improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy. Moreover, the combination's safety profile aligns with previously reported findings for the combo enfortumab vedotin - pembrolizumab in cisplatin-ineligible la/mUC patients.
$SGEN was trading at $214.00 in pre-market, up $7.61 (+3.69%) following the announcement
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login